Global Perspectives on Lymphoma in 2021 and Beyond

Clinical experts from the US discuss global perspectives on current treatment strategies and emerging therapies for lymphomas: T-cell, Hodgkin, MZL/Waldenström macroglobulinemia, DLBCL, FL, and MCL.

September 23 and 30, 2021
Purchase Report

FACULTY CHAIR

Brad S. Kahl, MD

Washington University School of Medicine, St. Louis, MO, US

Faculty Members

Stefan Barta MD, MS, MRCPCUK
University of Pennsylvania Health System, Philadelphia, PA, USA

John Allan, MD
Weill Cornell Medicine, New York, NY, USA

Kieron Dunleavy, MD
George Washington Cancer Center, Washington, DC, USA

Peter Martin, MD
Weill Cornell Medicine/Cornell University, New York City, NY, USA

Paolo Caimi, MD
Case Comprehensive Cancer Center, Cleveland, OH, USA

Luhua (Michael) Wang, MD
MD Anderson Cancer Center, Houston, TX, USA

Matthew Lunning, DO, FACP
University of Nebraska Medical Center, Omaha, NE, USA

 

 

Sample Report

Start discovering the insights

View Report

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

  • Current and Evolving Treatments for T-Cell Lymphomas  
  • Current and Evolving Treatments for Hodgkin Lymphoma 
  • Current and Evolving Treatments for MZL/Waldenström Macroglobulinemia 
  • Current and Evolving Treatments for DLBCL 
  • Current and Evolving Treatments for FL 
  • Current and Evolving Treatments for CLL/SLL 
  • Current and Evolving Treatments for MCL 

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.